We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Rituximab bio-similar for the treatment of myasthenia gravis (adults)
NHS England has concluded that there is sufficient evidence to support the routine commissioning of this treatment for patients who fulfil the criteria listed in this document.
